Table 3.
Comparison of antibiotic resistance of MRSA strains isolated from bloodstream infections in sickle cell disease (SCD) patients, Riyadh, Saudi Arabia (N = 34) Between Male (N = 24) and Female (N = 10) patients
| Antibiotic | Breakpoints* | Antibiotic resistance (N) and percent (%) | Male (N = 24) | Female (N = 10) | **p-Value |
|---|---|---|---|---|---|
| Amoxicillin | MRSA is intrinsically resistant | 34 (100) | 24 | 10 | 0.000 |
| Ampicillin | MRSA is intrinsically resistant | 34 (100) | 24 | 10 | 0.000 |
| Azithromycin | ≥ 8 µg/mL | 10 (29.4) | 8 | 2 | 0.023 |
| Cefazolin | MRSA intrinsically resistant | 34 (100) | 24 | 10 | 0.000 |
| Ciprofloxacin | ≥ 4 µg/mL | 10 (29.4) | 6 | 4 | 0.656 |
| Clindamycin | ≥ 4 µg/mL | 6 (17.6) | 4 | 2 | 0.567 |
| Erythromycin | ≥ 8 µg/mL | 12 (35.3) | 8 | 4 | 0.220 |
| Imipenem | MRSA intrinsically resistant | 34 (100) | 24 | 10 | 0.000 |
| Moxifloxacin | ≥ 1 µg/mL | 10 (29.4) | 6 | 4 | 0.656 |
| Oxacillin | ≥ 4 µg/mL | 34(100) | 24 | 10 | 0.000 |
| Penicillin | ≥ 0.25 µg/mL | 34 (100) | 24 | 10 | 0.020 |
| Tetracycline | ≥ 16 µg/mL | 11(32.4) | 8 | 3 | 0.086 |
| Tobramycin | ≥ 16 µg/mL | 1 (2.9) | 1 | 0 | 1 |
*CLSI M100 (2024 edition). ** If the P-value is more than 0.05, this means that the observed difference in resistance between males and females to this antibiotic is not statistically significant. The statistical analysis was performed using Chi-squared test in SPSS (IBM SPSS Statistics 29, USA)